The ovarian cancer market was valued at $1.8bn in 2018 across the seven major markets (7MM*), and it is expected to grow to $6.7bn in the following ten years with a compound annual growth rate (CAGR) of 14.4% according to GlobalData, a leading data and analytics company.
According to the company’s latest report, ‘Ovarian Cancer: Opportunity Analysis and Forecasts to 2028’, the main drivers of growth will be the adoption of maintenance therapy across the 7MM, poly ADP-ribose polymerase (PARP) inhibitor uptake in the first-line setting, the launch of new pipeline agents, and increased screening rates for genetic markers.
Ufuk Ezer, Oncology and Hematology Analyst at GlobalData, explains: “The dramatic growth in the ovarian cancer market is largely attributed to the label expansions for PARP inhibitors such as Lynparza, Zejula and Rubraca. The increase in screening rates for genetic markers such as BRCA mutations and other homologous recombination deficiencies (HRDs) will enable better patient segmentation and are expected to further drive the use of PARP inhibitors.”
In 2028, three PARP inhibitor drugs are expected to have combined revenue of $2.8bn, constituting more than 40% of the global ovarian cancer market. Moreover, by 2028, another major revenue contributor will be new drug classes – notably, immune checkpoint inhibitors, with five expected to enter the market bringing combined forecasted revenues of around $1.4bn.
Ezer continues: “Combining maintenance treatment with PARP inhibitors is regarded as a major step forward in extending the lives of ovarian cancer patients. Through 2028, PARP inhibitors will occupy more space in the first-line treatment setting. In addition to Lynparza’s label expansion that was granted in 2018, Zejula, Rubraca and Abbvie’s new PARP inhibitor veliparib will also appear in the first line setting. Moreover, launches of immune checkpoint inhibitors Tecentriq, dostarlimab, Opdivo, Imfinzi and Keytruda will help transform the treatment landscape that has been stagnant in previous decades.”
A major barrier for growth in the ovarian cancer market, however, will be the emerging use of biosimilars and generics for some key marketed products, namely Lynparza and angiogenesis inhibitor Avastin.
Ezer adds: “Despite advancements in the treatment of newly-diagnosed ovarian cancer patients, one of the largest unmet needs, the need for effective treatment options for the relapsed platinum-resistant patients, will remain unaddressed.
“In addition, the unmet need for early-stage diagnostic biomarkers and specialized treatment options for rare histological subtypes of ovarian cancer will also remain, which will provide further opportunities for diagnostics companies and drug developers.”
*7MM = US, France, Germany, Italy, Spain, UK and Japan.